Overview
PRAX market data
Price History
PRAX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$13.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.83 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,137.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $37.19 – $382.54 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $10.2B · P/B 8.39 · P/S 1,197.89.
Company News
RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462Benzinga · Aug 7, 2026, 8:03 PM
Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362Benzinga · Aug 7, 2026, 1:57 PM
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582Benzinga · Aug 6, 2026, 6:23 PM
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On ThursdayBenzinga · Aug 6, 2026, 2:01 PM
8-K filing — Praxis Precision Medicines, Inc. (PRAX)SEC EDGAR · Aug 6, 2026, 12:31 PM
Praxis Precision Medicine shares are trading higher after the company reported better-than-expected Q2 EPS results.Benzinga · Aug 6, 2026, 12:26 PM
Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) EstimateBenzinga · Aug 6, 2026, 12:03 PM
BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price TargetBenzinga · Jul 29, 2026, 10:30 AM
Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447Benzinga · Jul 13, 2026, 9:41 AM
Praxis Precision Medicines And Remagine Labs Announce Research Collaboration And License Agreement To Develop Iontophoretic Transdermal Patch For Delivery Of Ulixacaltamide For Essential TremorBenzinga · Jul 7, 2026, 12:10 PM